Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low disease activity a valid target in early SLE, investigators say

Key clinical point: Lupus low disease activity state (LLDAS) may be a valid alternative to complete remission (CR) as a treatment target in patients with newly diagnosed systemic lupus erythematosus (SLE).

Major finding: Achieving LLDAS and CR at 6-month follow-up were both independently associated with lower damage accrual at 18 months (odds ratios of 0.25 and 0.07, respectively).

Study details: Retrospective, single-center study including 118 adults with newly diagnosed SLE.

Disclosures: The authors reported no funding or competing interests related to their research.


Floris A et al. Arthritis Care Res. 2019 Oct 10. doi: 10.1002/acr.24086.